Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

- New data, updated since ASCO, show time without tumor growth now reaches

nearly 5 months with RAD001 vs. 1.9 months with placebo - One quarter of patients in trial remained progression-free beyond ten

months of treatment - RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent(R) or Nexavar(R)**, with potential to address unmet medical

need - RAD001 under review by regulatory authorities; potential to be first

once-daily oral mTOR therapy for advanced kidney cancer

EAST HANOVER, N.J., Sept. 16 /PRNewswire-FirstCall/ -- New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies.

Updated study findings from the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) study show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value < 0.001). In addition, after more than 10 months of treatment with RAD001, 25% of patients still had no tumor growth.

The updated RECORD-1 data were presented today at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, Sweden.

"These study results show the potential of RAD001 to continue working over an extended period of time in patients with advanced kidney cancer that progressed despite treatment with standard therapies," said Bernard Escudier, MD, Head of Immunotherapy and Innovative Therapy Unit, Gustave-Roussy Institute, Paris, France. "Based on these findings, I believe RAD001 should become part of the treatment paradigm for this patient population."

RAD001 has the potential to fill a currently unmet medical need and become the first approved therapy to demonstrate significant benefit in patients with advanced kidney ca
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Memorial Hermann Health System and The ... a new partnership to provide a new level of specialized ... in the greater Houston area. ... exclusive provider of professional breast radiology services for five of ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... ANGELES , Aug. 21, 2014 The spinal ... of the human body. Signals carried to and from the ... motor skills and nervous system. Injury or ailment here can ... or with a loss of control over their body. Though ... on a person,s life, there are more options available to ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 2011 Reportlinker.com announces that a new market ... Hospital MRI (Magnetic Resonance Imaging/Tomography) Census ... This is the most comprehensive European market report ... (General Radiology, Mammography, R&F, Angiography, CT, MRI,) and ...
... PITTSBURGH, Jan. 20, 2011 Mylan Inc. (Nasdaq: ... Laboratories Limited has received tentative approval from the U.S. ... Plan for AIDS Relief (PEPFAR) for its New Drug ... mg. The NDA is based on the reference listed ...
Cached Medicine Technology:Reportlinker Adds Hospital MRI (Magnetic Resonance Imaging/Tomography) Census 2Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Legal ... system created by Greg Marks has been generating a ... this month. The commotion surrounding the new product has ... investigative review. , “In recent years the ... software systems, commonly referred to as robots or ‘bots,'” ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final ... of ProIntro Vol.3, a customizable title tool for FCPX ... just by dragging ProIntro Vol.3 in their timeline" says Christina ... definite time saver and i think our users will agree" ... designed titles made with Final Cut Pro X users in ...
(Date:8/23/2014)... Teen substance abuse ranks as one of ... NC. Countless adolescents throughout North Carolina struggle with a drug ... never receive professional rehab due to a lack of information ... help. Troubled Teens Holly Springs is a helpline designed to ... teenage alcohol abusers in Wake County who are seeking ...
(Date:8/22/2014)... 2014 On Friday, Aug. 22, Liberty ... Health Sciences , hosting a ceremony in its courtyard ... government and public welfare. , The 162-member inaugural class ... (LUCOM) joined Liberty staff, faculty, and community leaders ... the new medical school. Classes began on Monday, Aug. ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... A-I ratio is not a better predictor of coronary ... total cholesterol and HDL-C, according to a study in ... instruments and guidelines for coronary heart disease (CHD) prevention ... cholesterol, or both for CHD risk assessment. But in ...
... scale, multiethnic study of its kind, researchers at UCLA ... known as cytokines as a cause of Type 2 ... biological markers that may be used to more accurately ... , Reporting in the August 15 issue of the ...
... improve their understanding of the potential increased risk of ... study conducted by researchers from The Childrens Hospital in ... New Haven, CT. , Like many radiology departments around ... exposure to children caused by increased usage of CT. ...
... Columbia University Medical Center researchers have demonstrated using ... was increased in stroke and traumatic brain injury ... rehabilitative treatment that helps these patients recover lost ... the peer-reviewed journal Neurorehabilitation and Neural Repair on ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic ... this study, Joseph Delaney MSc, Dr. James Brophy ... cases with a diagnosis of gastrointestinal bleeding and ... documented a 46-fold increase in the rate of ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2
Take Performance to a Higher Level....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
Medicine Products: